Trial Profile

An Open Label, Dose Exploration, Safety and Tolerability Study of a Subretinal Injection of an OPGx-001 Gene Vector to Participants With LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPGx-001 (Primary)
Indications Leber congenital amaurosis
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Acronyms LCA5-IRD
Sponsors Opus Genetics

Most Recent Events

06 Jun 2025 Planned End Date changed from 30 Jan 2028 to 15 Jun 2028.
06 Jun 2025 Planned primary completion date changed from 30 Dec 2024 to 15 Jun 2028.
15 May 2025 According to an Opus Genetics media release, pediatric cohort is expected to complete enrollment in the second quarter of 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com